Lisa Clive's Stock Ratings

Bernstein Analyst

Lisa Clive is an analyst at Bernstein. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/16/2025

Updated: Dec 16, 2025
Buy NowGet Alert
10/14/2025SNNBuy Now
Smith & Nephew
$32.1816.53%
Lisa Clive
 → $37.5DowngradeOutperform → Market PerformGet Alert

Recent Analyst Stock Rating News

Warren Buffett's Berkshire Hathaway Sells $116M Shares Of Dialysis Giant DaVita, Cuts Stake By 2%
Warren Buffett's Berkshire Hathaway Sells $116M Shares Of Dialysis Giant DaVita, Cuts Stake By 2%
Warren Buffett's investment firm, Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), has offloaded a 2% stake in dialysis service provider, DaVita Inc. (NYSE: DVA). The transaction, executed between February 14 and 19, is valued at around $116 million.
Alphabet To Rally Over 10%? Here Are 10 Other Analyst Forecasts For Wednesday
Alphabet To Rally Over 10%? Here Are 10 Other Analyst Forecasts For Wednesday
Citigroup raised the price target for LyondellBasell Industries N.V. (NYSE: LYB) from $104 to $106. Citigroup analyst Patrick Cunningham upgraded the stock from Neutral to Buy. LyondellBasell Industries shares gained 0.4% to close at $93.79 on Tuesday.
Bernstein Lowers DaVita's Price Target, Believes Dialysis Biz Is Well Positioned For Long-Term Growth
Bernstein Lowers DaVita's Price Target, Believes Dialysis Biz Is Well Positioned For Long-Term Growth
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved